Health News Releases

  • Today February 19
February 17, 2015 14:00
Eppendorf Announces New CryoCube® Ultra-Low Temperature Freezers
The new CryoCube (www.nbsc.com/freezers) F570, F570h, FC660, and FC660h ultra-low temperature freezers combine maximum sample security with improved functionality. New advancements decrease power cons
February 13, 2015 13:10
Manufacturing Authorization of Gene Therapy Medicinal Products Granted to CELLforCURE, the LFB Group Subsidiary Specialized in Innovative Therapies
CELLforCURE, a pharmaceutical establishment since October 2013 for the manufacturing of cell therapy medicinal products, was granted a new manufacturing authorization on January 30th, 2015. Delivered
February 12, 2015 15:25
Addition of Stent Thrombectomy in Treatment of Acute Ischemic Stroke Patients Reduces Disability in Global Studies
Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire™ D
February 10, 2015 16:00
Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial evaluating the safety and efficacy of ixazom
February 02, 2015 17:50
Ferring Pharmaceuticals Moves to Strengthen Growth with Appointment of Chief Medical and Chief Scientific Officers
Ferring Pharmaceuticals announced today the appointment of Pascal Danglas, MD as Executive Vice President and Chief Medical Officer and Per Falk, MD, PhD as Executive Vice President and Chief Scientif
January 30, 2015 17:30
Ortho Clinical Diagnostics and Quotient Announce Agreement to Commercialize Innovative Transfusion Diagnostic Platform, MosaiQ™
Ortho-Clinical Diagnostics, Inc. (“OCD”) announced it has entered into an exclusive agreement with commercial-stage diagnostics company Quotient Limited (“Quotient”) to distribute and sell Quotient’s
January 28, 2015 10:45
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (
January 27, 2015 17:30
New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD
For media outside the US, the UK and Canada Boehringer Ingelheim today announced that the first patient has been enrolled into its large-scale DYNAGITO® study.[1] It will assess the potential benef
January 20, 2015 22:05
Eppendorf Announces New BioFlo® 320 Bench Scale Bioprocess Control Station
The BioFlo 320 is truly a step into the future for Eppendorf as a bioprocess equipment manufacturer. New features including autoclavable and single-use vessel flexibility, intelligent sensors, and IP
January 19, 2015 17:45
OFEV® (nintedanib*) approved in the EU for the treatment of IPF
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHM
January 19, 2015 11:00
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis
Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA® (apremila
January 16, 2015 13:10
Expression Analysis Announces 2014 Grant Winners
Expression Analysis (EA), a Quintiles company, today announced the winners of a grant program that provides scientists with leading-edge products and services to advance genomics research. In this six
January 15, 2015 23:30
Clinicians Worldwide Confirm Impact of UpToDate on Quality of Care in 2014
Wolters Kluwer Health (http://goo.gl/o2rWK), a leading global provider of information for healthcare professionals and students, announced today that clinicians worldwide accessed more than 314 millio
January 15, 2015 17:45
35 Partners from Industry and Academia to Join European Research Initiative for the Prevention of Alzheimer’s Dementia
The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.
January 15, 2015 10:45
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim announced today that it has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory of Professor Stephen W. Fesik, Ph.D., the Orrin H.
January 14, 2015 11:25
Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas
Boehringer Ingelheim announced today collaboration with Yale University, New Haven, Connecticut, USA, with the goal of researching novel therapeutic targets in the field of immune-modulation. Immune-m
January 12, 2015 23:00
Dako, an Agilent Technologies Company, and Cell Signaling Technology announce partnership within companion diagnostics
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Cell Signaling Technology (CST), a worldwide provider of antibodies, today announced that they have entered in
January 12, 2015 16:40
The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy
Boehringer Ingelheim today announced overall survival (OS) results were published in The Lancet Oncology from two independent Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6) in epidermal growth
December 26, 2014 11:10
PPD and SNBL Announce Japanese Clinical Development Joint Venture and Additional Collaborations
Pharmaceutical Product Development, LLC (PPD, www.ppdi.com) and Shin Nippon Biomedical Laboratories Ltd. (SNBL, http://snbl.com) (TSE:2395) today announced an agreement to form a joint venture that wi
December 22, 2014 13:35
Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (
December 18, 2014 14:00
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical Treatment for Acute Ischemic Stroke Patients
In a landmark study evaluating the addition of stent thrombectomy clot removal to pharmaceutical treatment for patients suffering an acute ischemic stroke (AIS), stent thrombectomy provided a signific
December 18, 2014 14:00
LFB S.A. Announces Achievement of Patient Enrollment Target for PerSept 1 Program for the Evaluation of Recombinant Factor Seven Efficacy by Prospective Clinical Trials
LFB S.A. announced today the achievement of patient enrollment target for PERSEPT 1, a multinational Phase 3 clinical trial of LR769, a novel recombinant form of human Factor VIIa, in adolescent and a
December 17, 2014 16:45
Ossianix Expands and Extends Its Research Collaboration with Lundbeck on CNS Therapeutics
Ossianix, Inc. today announced an expansion and extension of its strategic research collaboration with H. Lundbeck A/S (Lundbeck). This collaboration follows a previous equity investment in 2012 and p
December 16, 2014 09:55
First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investigate the efficacy and safety of dabigatr
December 12, 2014 22:00
Terumo BCT Congratulates Two Recipients of 2014 Advancing Apheresis Awards
Vanderbilt University Medical Center and The Royal Children’s Hospital in Melbourne, Australia (RCH) are driving toward new possibilities with help from Terumo BCT’s 2014 Advancing Apheresis Awards. T
25 per page50 per page75 per page100 per page